Search

Author/Creator Gore, M

3. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. (13th July 2018)

Authors:
Corrie, P G; Marshall, A; Nathan, P D; Lorigan, P; Gore, M; Tahir, S; Faust, G; Kelly, C G; Marples, M; Danson, S J; Marshall, E; Houston, S J; Board, R E; Waterston, A M; Nobes, J P; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A
Journal:
Annals of oncology
Issue:
Volume 29:Number 8(2018)
Page Start:
1843
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. (20th August 2019)

Authors:
Corrie, P G; Marshall, A; Nathan, P D; Lorigan, P; Gore, M; Tahir, S; Faust, G; Kelly, C G; Marples, M; Danson, S J; Marshall, E; Houston, S J; Board, R E; Waterston, A M; Nobes, J P; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A
Journal:
Annals of oncology
Issue:
Volume 30:Number 12(2019)
Page Start:
2013
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗